Roivant Sciences (Roivant Sciences) EV-to-Revenue

: 18.25 (As of Today)

View and export this data going back to 2021. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Roivant Sciences's enterprise value is $2,248.8 Mil. Roivant Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $123.2 Mil. Therefore, Roivant Sciences's EV-to-Revenue for today is 18.25.

The historical rank and industry rank for Roivant Sciences's EV-to-Revenue or its related term are showing as below:

ROIV' s EV-to-Revenue Range Over the Past 10 Years
Min: 18.5 Med: 63 Max: 149.89
Current: 18.25

During the past 3 years, the highest EV-to-Revenue of Roivant Sciences was 149.89. The lowest was 18.50. And the median was 63.00.

ROIV's EV-to-Revenue is ranked worse than
68.12% of 1032 companies
in the Biotechnology industry
Industry Median: 7.615 vs ROIV: 18.25

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-18), Roivant Sciences's stock price is $10.36. Roivant Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.16. Therefore, Roivant Sciences's PS Ratio for today is 65.99.

Roivant Sciences EV-to-Revenue Historical Data

The historical data trend for Roivant Sciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Annual Data

Trend

Mar21

Mar22

Mar23

EV-to-Revenue

37.28

79.38

Roivant Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue											121.29	79.38	91.81	85.50	27.34

Competitive Comparison

For the Biotechnology subindustry, Roivant Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roivant Sciences EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Roivant Sciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's EV-to-Revenue falls into.

Roivant Sciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Roivant Sciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2248.801	/	123.241
	=	18.25

Roivant Sciences's current Enterprise Value is $2,248.8 Mil.
Roivant Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $123.2 Mil.

Roivant Sciences (NAS:ROIV) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Roivant Sciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	10.36	/	0.157
	=	65.99

Roivant Sciences's share price for today is $10.36.
Roivant Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16.

Roivant Sciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Roivant Sciences (Roivant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

87S:Germany

Address

50 Broadway, 7th Floor, London, GBR, SW1H 0BD

Website

https://www.roivant.com

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Executives

Eric Venker	officer: President & COO	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester	director	C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold	director	6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp	10 percent owner, other: Director by Deputization	888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar	officer: Chief Accounting Officer	C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p.	10 percent owner	AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik	officer: CFO	SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy	director	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000